Geron Corporation (GERN)

NASDAQ
Currency in USD
2.7750
-0.0450(-1.60%)
Real-time Data
GERN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
2.75002.8300
52 wk Range
1.64005.3400
Key Statistics
Edit
Prev. Close
2.82
Open
2.81
Day's Range
2.75-2.83
52 wk Range
1.64-5.34
Volume
3.78M
Average Volume (3m)
10.63M
1-Year Change
33.65%
Book Value / Share
0.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GERN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
7.8750
Upside
+183.78%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Geron Corporation Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation SWOT Analysis


Imetelstat's Promise
Geron's lead product shows efficacy in treating myelodysplastic syndromes and myelofibrosis, positioning the company as a potential key player in oncology
Financial Trajectory
Analysts project 311.66% revenue growth for FY2024 and potential profitability by H2 2025, despite current negative earnings
Market Dynamics
Explore Geron's commercial launch of Rytelo and its strategic IP approach, potentially securing market exclusivity beyond 2035
Growth Horizons
Analysts maintain a bullish consensus with an average price target of $9.00, citing label expansion potential and strong revenue projections
Read full SWOT analysis

Geron Corporation Earnings Call Summary for Q2/2024

  • RYTELO launch shows promise: 160 patients treated, 60% penetration in top US accounts, included in NCCN Guidelines
  • Geron expects national coverage policies by Q1 2025, with robust commercial infrastructure in place
  • Solid financials: $430M cash as of June 30, 2024; operations funded into Q2 2026
  • 2024 operating expenses projected at $270M-$280M; no sales projections provided yet
  • CEO expresses satisfaction with launch progress; reimbursement issues not encountered
Last Updated: 09/08/2024, 10:12 am
Read Full Transcript

Compare GERN to Peers and Sector

Metrics to compare
GERN
Peers
Sector
Relationship
P/E Ratio
−8.3x−3.1x−0.6x
PEG Ratio
−1.59−0.150.00
Price/Book
5.7x1.3x2.6x
Price / LTM Sales
56.9x42.3x3.1x
Upside (Analyst Target)
183.7%216.4%48.7%
Fair Value Upside
Unlock23.3%7.7%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.8750
(+183.78% Upside)

Earnings

Latest Release
Nov 07, 2024
EPS / Forecast
-0.04 / -0.08
Revenue / Forecast
28.27M / 18.92M
EPS Revisions
Last 90 days

People Also Watch

1.270
HOLO
-3.79%
16.3200
ADMA
-2.04%
32.60
NNE
-7.14%
1.910
QSI
-4.50%
3.18
IBRX
-6.19%

FAQ

What Is the Geron (GERN) Stock Price Today?

The Geron stock price today is 2.775

What Stock Exchange Does Geron Trade On?

Geron is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Geron?

The stock symbol for Geron is "GERN."

What Is the Geron Market Cap?

As of today, Geron market cap is 1.68B.

What is Geron Earnings Per Share?

The Geron EPS is -0.32.

What Is the Next Geron Earnings Date?

Geron will release its next earnings report on 05 Mar 2025.

From a Technical Analysis Perspective, Is GERN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.